Skip to main content
Veterinary Medicines

Vanguard CPV Suspensie voor injectie

Authorised
  • Canine parvovirus, strain NL-35-D, Live

Product identification

Medicine name:
Vanguard CPV Suspensie voor injectie
Vanguard CPV Suspension injectable
Vanguard CPV Injektionslösung
Active substance:
  • Canine parvovirus, strain NL-35-D, Live
Target species:
  • Dog
Route of administration:
  • Subcutaneous use

Product details

Active substance and strength:
  • Canine parvovirus, strain NL-35-D, Live
    10000000.00
    cell culture infective dose 50
    /
    1.00
    millilitre(s)
Pharmaceutical form:
  • Suspension for injection
Withdrawal period by route of administration:
  • Subcutaneous use
    • Dog
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI07AD01
Authorisation status:
  • Valid
Authorised in:
  • Belgium
Package description:
  • Vanguard CPV 100 Vials with 1 dose of Suspension for injection
  • Vanguard CPV 25 Vials with 1 dose of Suspension for injection
  • Vanguard CPV 10 Vials with 1 dose of Suspension for injection
  • Vanguard CPV 1 Vial with 1 dose of Suspension for injection

Additional information

Entitlement type:
  • Marketing Authorisation
Marketing authorisation holder:
  • Zoetis Belgium
Marketing authorisation date:
Manufacturing sites for batch release:
  • Zoetis Belgium
Responsible authority:
  • Federal Agency For Medicines And Health Products
Authorisation number:
  • BE-V161576
Date of authorisation status change:

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
Dutch (PDF)
Published on: 22/03/2022
French (PDF)
Published on: 22/03/2022

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.
Dutch (PDF)
Published on: 22/03/2022
French (PDF)
Published on: 22/03/2022
German (PDF)
Published on: 22/03/2022
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."